伏美替尼联合全脑放疗治疗非小细胞肺癌脑转移患者的临床效果  

Clinical effect of furmonertinib combined with whole brain radiotherapy in the treatment of non-small cell lung cancer patients with brain metastases

作　　者：袁燕 梁博 肖正红 YUAN Yan;LIANG Bo;XIAO Zhenghong(Department of Radiotherapy,Nanshi Hospital of Nanyang,Nanyang 473000,He'nan,China;Department of Oncology,Nanshi Hospital of Nanyang,Nanyang 473000,He'nan,China)

机构地区：[1]南阳南石医院放疗科,河南南阳473000 [2]南阳南石医院肿瘤科,河南南阳473000

出　　处：《癌症进展》2024年第21期2424-2427,共4页Oncology Progress

摘　　要：目的 探讨伏美替尼联合全脑放疗治疗非小细胞肺癌(NSCLC)脑转移患者的临床效果。方法 将90例NSCLC脑转移患者根据治疗方案的不同分为对照组47例和研究组43例。对照组患者采取吉非替尼联合全脑放疗,研究组患者采取伏美替尼联合全脑放疗。比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]、不良反应发生情况以及生活质量[肺癌患者生命质量测定量表(FACT-L)]。结果 研究组患者疾病控制率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者CYFRA21-1、CA19-9、CEA水平均较治疗前降低,且研究组患者CYFRA21-1、CA19-9、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者FACT-L各维度评分均较治疗前升高,且研究组患者FACT-L各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论 伏美替尼联合全脑放疗治疗NSCLC脑转移患者有一定的疗效,可降低肿瘤标志物水平,提高患者生活质量,且具有一定的安全性。Objective To investigate the clinical effect of furmonertinib combined with whole brain radiotherapy in the treatment of non-small cell lung cancer(NSCLC)patients with brain metastases.Method A total of 90 NSCLC patients with brain metastases were divided into control group(47 cases)and study group(43 cases)according to different treatment regimens.The control group received gefitinib combined with whole brain radiotherapy,and the study group received furmonertinib combined with whole brain radiotherapy.The clinical efficacy,tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],incidence of adverse reactions and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups.Result The disease control rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,CA19-9 and CEA in two groups were lower than those before treatment,and the levels of CYFRA21-1,CA19-9 and CEA in study group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the scores of all dimensions of FACT-L in the two groups were higher than those before treatment,and the scores of all dimensions of FACT-L in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Furmonertinib combined with whole brain radiotherapy is effective in the treatment of NSCLC patients with brain metastases,can reduce the level of tumor markers,improve the quality of life,and has a certain safety.

关 键 词：肺癌 脑转移 伏美替尼 全脑放疗 

分 类 号：R734.2[医药卫生—肿瘤]